» Articles » PMID: 27137218

Neuropsychiatric Disturbances in Alzheimer's Disease: What Have We Learned from Neuropathological Studies?

Overview
Specialty Neurology
Date 2016 May 4
PMID 27137218
Citations 30
Authors
Affiliations
Soon will be listed here.
Abstract

Neuropsychiatric symptoms (NPS) are an integral part of the dementia syndrome and were therefore recently included in the core diagnostic criteria of dementia. The near universal prevalence of NPS in Alzheimer's disease (AD), combined with their disabling effects on patients and caregivers, is contrasted by the fact that few effective and safe treatments exist, which is in part to be attributed to our incomplete understanding of the neurobiology of NPS. In this review, we describe the pathological alterations typical for AD, including spreading and evolution of burden, effect on the molecular and cellular integrity, functional consequences and atrophy of NPS-relevant brain regions and circuits in correlation with specific NPS assessments. It is thereby clearly established that NPS are fundamental expressions of the underlying neurodegenerative brain disease and not simply reflect the patients' secondary response to their illness. Neuropathological studies, moreover, include a majority of end-stage patient samples, which may not correctly represent the pathophysiological environment responsible for particular NPS that may already be present in an early stage, or even prior to AD diagnosis. The burdensome nature and high prevalence of NPS, in combination with the absence of effective and safe pharmacotherapies, provide a strong incentive to continue neuropathological and neurochemical, as well as imaging and other relevant approaches to further improve our apprehension of the neurobiology of NPS.

Citing Articles

Exploring the Complex Relationship Between Antidepressants, Depression and Neurocognitive Disorders.

Neatu M, Ionita I, Jugurt A, Davidescu E, Popescu B Biomedicines. 2025; 12(12.

PMID: 39767653 PMC: 11727177. DOI: 10.3390/biomedicines12122747.


Monoamine alterations in Alzheimer's disease and their implications in comorbid neuropsychiatric symptoms.

Saggu S, Bai A, Aida M, Rehman H, Pless A, Ware D Geroscience. 2024; 47(1):457-482.

PMID: 39331291 PMC: 11872848. DOI: 10.1007/s11357-024-01359-x.


Distinguishing features of depression in dementia from primary psychiatric disease.

Fisher D, Dunn J, Dong H Discov Ment Health. 2024; 4(1):3.

PMID: 38175420 PMC: 10767128. DOI: 10.1007/s44192-023-00057-y.


Advanced Immunolabeling Method for Optical Volumetric Imaging Reveals Dystrophic Neurites of Dopaminergic Neurons in Alzheimer's Disease Mouse Brain.

Baek S, Jang J, Jung H, Lee H, Choe Y Mol Neurobiol. 2023; 61(7):3976-3999.

PMID: 38049707 PMC: 11236860. DOI: 10.1007/s12035-023-03823-9.


Neuropsychiatric features in a multi-ethnic population with Alzheimer disease and mild cognitive impairment.

Celis K, Zaman A, Adams L, Gardner O, Farid R, Starks T Int J Geriatr Psychiatry. 2023; 38(9):e5992.

PMID: 37655494 PMC: 10518518. DOI: 10.1002/gps.5992.


References
1.
Teipel S, Hampel H . Neuroanatomy of Down syndrome in vivo: a model of preclinical Alzheimer's disease. Behav Genet. 2006; 36(3):405-15. DOI: 10.1007/s10519-006-9047-x. View

2.
Najjar S, Pearlman D, Alper K, Najjar A, Devinsky O . Neuroinflammation and psychiatric illness. J Neuroinflammation. 2013; 10:43. PMC: 3626880. DOI: 10.1186/1742-2094-10-43. View

3.
Marsh S, Blurton-Jones M . Examining the mechanisms that link β-amyloid and α-synuclein pathologies. Alzheimers Res Ther. 2012; 4(2):11. PMC: 4054672. DOI: 10.1186/alzrt109. View

4.
Choi J, Rees H, Weintraub S, Levey A, Chin L, Li L . Oxidative modifications and aggregation of Cu,Zn-superoxide dismutase associated with Alzheimer and Parkinson diseases. J Biol Chem. 2005; 280(12):11648-55. DOI: 10.1074/jbc.M414327200. View

5.
Donev R, Kolev M, Millet B, Thome J . Neuronal death in Alzheimer's disease and therapeutic opportunities. J Cell Mol Med. 2009; 13(11-12):4329-48. PMC: 4515050. DOI: 10.1111/j.1582-4934.2009.00889.x. View